Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma
Open accessThe DOI matches its Crossref record.
Abstract
Abstract Background Lenvatinib (LEN) is a multikinase inhibitor of VEGFR1–3 and other targets. We report data from phase Ib dose-finding and phase II expansion cohorts of LEN + etoposide + ifosfamide in pts with r/r osteosarcoma. Methods Pts were aged 2 to ≤ 25 years with r/r osteosarcoma and Results In the phase Ib dose-finding cohort (n = 22), pts received LEN 11 mg/m2 (n = 7) and 14 mg/m2 (n = 15) + chemo. Dose-limiting toxicities were: Grade (G) 4 thrombocytopenia (n = 1; LEN 11 mg/m2), G4 thrombocytopenia and G3 epistaxis (n = 1; LEN 14 mg/m2), G2 oral dysesthesia, G3 muscle spasm, and G2 back pain (n = 1; LEN 14 mg/m2). RPh2D was LEN 14 mg/m2 + chemo. In the expansion cohort (n = 20), the median number of LEN cycles received was 4 (range: 1–7). As reported in the database, the most frequent treatment-emergent adverse events (TEAEs) were platelet count decreased/thrombocytopenia (50%/30%), neutropenia/neutrophil count decreased (45%/25%), anemia (45%), nausea (40%), ALT increased, diarrhea, and white blood cell count decreased (30% each). Most frequent G ≥ 3 TEAEs were neutropenia/neutrophil count decreased (45%/25%), platelet count decreased/thrombocytopenia (40%/20%), white blood cell count decreased (30%), and anemia (25%). Pneumothorax was observed in the dose-finding cohort (n = 6) and expansion cohort (n = 1); 2 (dose-finding cohort) were ≥G3; and 1 was post-thoracotomy. 4 Pts (dose-finding cohort) discontinued treatment due to TEAEs. There were no treatment-related fatal serious AEs. In the dose-finding combination cohort, 12/18 evaluable pts (66.7%) achieved PFS-4. In the phase II expansion cohort, 5/8 evaluable pts (62.5%) achieved PFS-4. Conclusions The combination of RPh2D LEN (14 mg/m2) + chemo had a manageable safety profile with promising preliminary evidence of efficacy. Clinical trial identification NCT02432274. Legal entity responsible for the study Eisai Inc. Funding Eisai Inc. Disclosure A. Longhi: Non-remunerated activity/ies, non-financial support: PharmaMar, Takeda; Research grant / Funding (institution): Takeda. M. Casanova: Advisory / Consultancy, advisory role: Bayer; Advisory / Consultancy, advisory role: Lilly; Advisory / Consultancy, advisory role: Roche; Advisory / Consultancy, advisory role: Tesaro. S.S. Bielack: Travel / Accommodation / Expenses, site fees for study preparation: Eisai; Travel / Accommodation / Expenses, personal fees from Clinigen: Clinigen; Travel / Accommodation / Expenses, personal fees from Lilly: Lilly; Travel / Accommodation / Expenses, personal fees from Novartis: Novartis; Travel / Accommodation / Expenses, personal fees from Bayer: Bayer; Travel / Accommodation / Expenses, personal fees from Pfizer: Pfizer; Travel / Accommodation / Expenses, personal fees from Isofol: Isofol; Travel / Accommodation / Expenses, personal fees from Sensorion: Sensorion; Travel / Accommodation / Expenses, personal fees from Ipsen: Ipsen; Advisory / Consultancy, Institution negotiating consultancy agreement with Eisai: Eisai. S. Gallego Melcon: Travel / Accommodation / Expenses: Loxo Oncology; Advisory / Consultancy: Bayer, Eusa. All other authors have declared no conflicts of interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Palmerini, E., Setola, E., Grignani, G., D’Ambrosio, L., Comandone, A., Righi, A., Longhi, A., Cesari, M., Paioli, A., Hakim, R., et al. (2020) · Cells · doi:10.3390/cells9112389 · Cited by 36
Self-citationXie, L., Xu, J., Sun, X., Li, X., Liu, K., Liang, X., Zhou, Z., Zhuang, H., Sun, K., Wu, Y., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12813 · Cited by 19
“The results on lenvatinib and IE reported at the 2019 ESMO (23) showed promise for the future use of this combination, of which the median PFS was prolonged to 11.”
BackgroundInfluentialSchulte, B., Mohindra, N., Milhem, M., Attia, S., Robinson, S., Monga, V., Hirbe, A. C., Oppelt, P., Charlson, J., Helenowski, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01448-0 · Cited by 19
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
Self-citationGaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0743 · Cited by 9
Self-citation
Metadata
- Authors
- Gaspar, N., Sirvent, F. J. B., Venkatramani, R., Longhi, A., Lervat, C., Casanova, M., Aerts, I., Bielack, S. S., Entz-Werle, N., Strauss, S., He, C., Thebaud, E., Locatelli, F., Morland, B., Melcon, S. G., Nieto, A. C., Marec- Bérard, P., Gambart, M., Rossig, C., & Campbell-Hewson, Q.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Pages
- v688
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2977922663
- Cited by
- 9
- References
- 0
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma. https://app.cochat.ai/papers/10.1093/annonc/mdz283.009
- The paper
- Gaspar, N., Sirvent, F. J. B., Venkatramani, R., Longhi, A., Lervat, C., Casanova, M., Aerts, I., Bielack, S. S., Entz-Werle, N., Strauss, S., He, C., Thebaud, E., Locatelli, F., Morland, B., Melcon, S. G., Nieto, A. C., Marec- Bérard, P., Gambart, M., Rossig, C., & Campbell-Hewson, Q. (2019). Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma. Annals of Oncology. https://doi.org/10.1093/annonc/mdz283.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.